Clinical Investigators Focusing on benefits of Reolysin, Kyprolis Combination in Multiple Myeloma

26876

0 comment

Staff at TrialSite | Quality Journalism

Feb. 1, 2020, 4:30 p.m.

Oncolytics Biotech’s virus-based anti-cancer therapy Reolysin (pelareorep) has the attention of top researchers from Winship Cancer Center and City of Hope who are studying how combinations including pelareorep and Kyprolis (carfilzomib) offer benefits to multiple myeloma patients.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month
which is less than a Starbucks coffee!

Peter Gabriel, MD

"Publishing on TrialSite helped me secure a $20m research grant for my work."

Jona Savinda

"TrialSiteNews is my daily read for what is happening in the industry."